FRR Shares (Makes you Realise)

Equity

Home/ Are You A Trader/ Market Info/ Company Profile/ Smart Quotes

COMPANY PROFILE

GLAND PHARMA LTD.

NSE : GLANDBSE : 543245ISIN CODE : INE068V01023Industry : Pharmaceuticals & DrugsHouse : Private

BSE1919.3550.75 (+2.72 %)

PREV CLOSE (Rs.) 1868.60

OPEN PRICE (Rs.) 1849.25

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 3170

TODAY'S LOW / HIGH (Rs.)1849.25 1929.00

52 WK LOW / HIGH (Rs.)1200 2130

NSE1921.0042.9 (+2.28 %)

PREV CLOSE( Rs. ) 1878.10

OPEN PRICE (Rs.) 1878.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 1921.00 (119)

VOLUME 431248

TODAY'S LOW / HIGH(Rs.) 1871.50 1930.00

52 WK LOW / HIGH (Rs.)1277.8 2131

More From Company Profile

Smart Quotes

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Trade Value (Rs. in Lacs)

60.57

Dividend Yield(%)

0.94

TTM EPS (Rs.)

68.96

P/E Ratio

27.83

Book Value (Rs.)

608.43

Face Value (Rs.)

MCap (Rs. in Mn)

316225.24

Price/Earning (TTM)

24.17

Price/Sales (TTM)

7.63

Price/Book (MRQ)

3.15

PAT Margin (%)

26.48

ROCE (%)

15.87

Incorporation Year : 20-03 1978

Management Info :

Srinivas Sadu - Chairman - Managing Director

Registered Office :

Address : Survey No. 143-148, 150 & 151, Near Gandimaisamma ‘x’ Roads,D. P. Pally, Dundigal, Dundigal-gandimaisamma Mandal,Medchal- Malkajgiri District,
Hyderabad,
Telangana-500043

Phone : 040 30510999

Email : gland@glandpharma.com / investor@glandpharma.com

Website : www.glandpharma.com

Registrars Details :

MUFG Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE

NEWS

08Sep Gland Pharma informs about investor me
Pursuant to Regulation 30 read with Part A of the Securities and Exchang..

26Aug Gland Pharma receives USFDA’s approval
Gland Pharma has received approval from the United States Food and Drug..

12Aug Gland Pharma gets USFDA’s approval for
Gland Pharma has received approval from the United States Food and Drug..

Financials

	QTR Jun 25	ANNUAL 25
Net Profit	2692.58	10897.53
Gross Profit	3623.83	14655.85
Operating Profit	4135.86	16576.93
Net Sales	10388.35	41161.49

Rs. in Millions

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Astrazeneca Pharma I (BSE)

9105.75 (0.80%)

M.Cap (Rs. in Cr)22764.38

Glenmark Pharma (BSE)

2116.25 (3.10%)

M.Cap (Rs. in Cr)59720.75

Dr. Reddy's Lab (BSE)

1293.45 (3.45%)

M.Cap (Rs. in Cr)107952.28

Wockhardt (BSE)

1496.75 (2.54%)

M.Cap (Rs. in Cr)24321.02

Shareholding Pattern

	PROMOTERS	51.83%
	MUTUAL FUNDS/UTI	30.67%
	NON-INSTITUTION	7.93%
	FI/BANKS/INSURANCE	1.27%
	GOVERNMENT	0%
	FII	0%

Mf Holding

Scheme Name

Hold(%)

DSP Healthcare Fund...

5.52

ICICI Pru MNC Fund(G)

3.67

ICICI Pru Pharma He...

3.57

Nippon India Pharma...

3.27

HDFC Pharma and Hea...

3.10

UTI Healthcare Fund...

3.00

UTI MNC Fund-Reg(IDCW)

2.72

Attention Investors

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month, Issued in the interest of Investors.

Risk Disclosure on Derivatives | Smart ODR | Mandatory Display | KYC Validation Links

BSE / NSE SEBI Registration No. INZ000279232, Depository Participant SEBI Registration No. – IN DP CDSL 132-2015

Mutual funds - ARN No. 81648 , Investment Adviser SEBI Registration No. : INA000008668.

CLOSE X

Risk Disclosures On Derivatives

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22

GLAND PHARMA LTD.

Smart Quotes

Attention Investors

Download Client Registration Documents

Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do's & Don't's) in Vernacular Language :

Filing complaints on SCORESEasy & quick

Risk Disclosures On Derivatives